Level Biotechnology

Level Biotechnology ROA

The Return on Assets (ROA) of Level Biotechnology (3118.TWO) as of Nov 15, 2026 is 9.19 %. In the previous year, Return on Assets (ROA) was 7.84 % — a change of 17.34% (higher).

ROA

9.19 %

YoY

17.34%

Last updated:

In 2025, Level Biotechnology's return on assets (ROA) was 9.19 %, a 17.34% increase from the 7.84 % ROA in the previous year.

The Level Biotechnology ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
5.72 TWD
Jan 1, 2019
6.32 TWD
Jan 1, 2020
7.51 TWD
Jan 1, 2021
8.66 TWD
Jan 1, 2022
7.20 TWD
Jan 1, 2023
7.65 TWD
Jan 1, 2024
7.84 TWD
Jan 1, 2025
9.19 TWD
The Level Biotechnology ROA history
YEARROAYoY
9.19 %+17.34%
7.84 %+2.48%
7.65 %+6.27%
7.20 %-16.88%
8.66 %+15.28%
7.51 %+18.85%
6.32 %+10.47%
5.72 %-38.69%
9.33 %-0.32%
9.36 %-18.59%
11.50 %+1.96%
11.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

ROA Details

Understanding Level Biotechnology's Return on Assets (ROA)

Level Biotechnology's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Level Biotechnology's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Level Biotechnology's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Level Biotechnology’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Level Biotechnology stock

Return on Assets (ROA) of Level Biotechnology is 9.19 % in 2025.

Return on Assets (ROA) of Level Biotechnology changed from 7.84 % to 9.19 %, representing a 17.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Level Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Level Biotechnology

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Level Biotechnology